Adalimumab Biosimilar(Mycenax Biotech)

N/A

Report date: 2025/03/07 17:34:34

Base Information

Drug NameAdalimumab Biosimilar(Mycenax Biotech)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionImmunosuppressantsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsCrohn DiseaseArthritis, RheumatoidArthritis, Juvenile +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMycenax Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesMycenax Biotech Inc
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseArthritis, RheumatoidArthritis, Juvenile +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A